期刊
IMMUNITY
卷 53, 期 6, 页码 1315-+出版社
CELL PRESS
DOI: 10.1016/j.immuni.2020.11.015
关键词
-
类别
资金
- National Special Research Program of China for Important Infectious Diseases [2018ZX10302103, 2017ZX10202102]
- Special 2019-nCoV Program of Natural Science Foundation of China (NSFC) [82041002]
- Special 2019-nCoV Project of National Key Research and Development Program of China [2020YFC0841400]
- Important Key Program of NSFC [81730060]
- Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou [201803040002]
- National Postdoctoral Program for Innovative Talents
- General Program of China Postdoctoral Science Foundation [BX20190398, 2019M663215]
- Pearl River S&T Nova Program of Guangzhou [201806010118]
- Special 2019-nCoV Project of Research and Development Program of Guangdong [2020B111123001]
Various vaccine strategies have been proposed in response to the global COVID-19 pandemic, each with unique strategies for eliciting immune responses. Here, we developed nanoparticle vaccines by covalently conjugating the self-assembled 24-mer ferritin to the receptor binding domain (RBD) and/or heptad repeat (HR) subunits of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) spike (S) protein. Compared to monomer vaccines, nanoparticle vaccines elicited more robust neutralizing antibodies and cellular immune responses. RBD and RBD-HR nanoparticle vaccinated hACE2 transgenic mice vaccinated with RBD and/or RBD-HR nanoparticles exhibited reduced viral load in the lungs after SARS-CoV-2 challenge. RBD-HR nanoparticle vaccines also promoted neutralizing antibodies and cellular immune responses against other coronaviruses. The nanoparticle vaccination of rhesus macaques induced neutralizing antibodies, and T and B cell responses prior to boost immunization; these responses persisted for more than three months. RBD- and HR-based nanoparticles thus present a promising vaccination approach against SARS-CoV-2 and other coronaviruses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据